source
- Alumis' lupus trial misses endpoints, but company eyes phase 3 in IFNGS‑high subgroupAlumis reported that its phase 2b study of the TYK2 inhibitor envudeucitinib failed to meet both the primary and secondary efficacy endpoints in patients with moderate to severe systemic lupus eryt…
- Novocure cyberattack exposes data of over 1,400 U.S. patients and staffNovocure disclosed a cyberattack in an SEC filing, saying unauthorized access to some information systems was discovered in mid‑August. The breach exposed internal patient ID numbers for more than…